TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18567895

Group type: EXPERIMENTAL
Intervention: IVF/ICSI with Preimplantation Genetic Screening (PGS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IVF/ICSI without Preimplantation Genetic Screening (PGS)
Number of subjects: 0
Study: 16866595

Group type: EXPERIMENTAL
Intervention: Response reversal task with 2 reward‐punishment contingencies (100‐0 and 80‐20)
Number of subjects: 0
Study: 12627043

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol, 0.1 mg/day for 3 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Estrogen withdrawal after long-term ERT
Number of subjects: 20
Study: 10834770

Group type: EXPERIMENTAL
Intervention: Children with autism
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Children with developmental delays
Number of subjects: 39

Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 39
Study: 9987969

Group type: EXPERIMENTAL
Intervention: psychotherapy with biofeedback + hypotensive drugs
Number of subjects: 85

Group type: COMPARATOR
Intervention: hypotensive drugs only
Number of subjects: 85
Study: 7835550

Group type: EXPERIMENTAL
Intervention: Borderline essential hypertension subjects
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Group 2 (reduced nocturnal blood pressure fall)
Number of subjects: 59

Group type: COMPARATOR
Intervention: White coat hypertension subjects
Number of subjects: 59
Study: 3042011

Group type: EXPERIMENTAL
Intervention: recombinant alpha‐interferon (rIFN‐alpha 2a2) in combination with etretinate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: recombinant alpha‐interferon (rIFN‐alpha 2a2) alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination therapy (rIFN-alpha 2a2 + etretinate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: rIFN-alpha 2a alone
Number of subjects: 11
Study: 29569019

Group type: EXPERIMENTAL
Intervention: Breath VOC biomarkers analyzed with gas chromatography mass spectrometry (GC MS)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Breath VOC biomarkers analyzed with surface acoustic wave detection (GC SAW)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Low DF value
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: High DF value
Number of subjects: 178
Study: 29141055

Group type: EXPERIMENTAL
Intervention: 1,064 nm laser treatment (5 monthly treatments)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 532 nm laser treatment (4 monthly treatments)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study: 26065915

Group type: EXPERIMENTAL
Intervention: Chimney woodstove intervention (early stove households)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Delayed stove households (control)
Number of subjects: 306
Study: 23920036

Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20331373

Group type: EXPERIMENTAL
Intervention: Thermal ultrasound (3 MHz, 1.4 W/cm², 5 min, circular motion)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham ultrasound (ultrasound not turned on)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thermal ultrasound (over 2 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham ultrasound (over 2 weeks)
Number of subjects: 26
Study: 18248658

Group type: EXPERIMENTAL
Intervention: 10 mg amitriptyline daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16788419

Group type: EXPERIMENTAL
Intervention: Reconstruction of the TM with perichondrium/cartilage graft and intraoperative T-tube insertion
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reconstruction of the TM with perichondrium/cartilage graft without ventilation tube insertion
Number of subjects: 46
Study: 14639153

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 94
Study: 10869928

Group type: EXPERIMENTAL
Intervention: Corticosteroids (Methylprednisolone)
Number of subjects: 0
Study: 8619207

Group type: EXPERIMENTAL
Intervention: Erythropoietin (150 IU/kg body weight, subcutaneously every 2 days for 10 days before operation until postoperative day 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1402311

Group type: EXPERIMENTAL
Intervention: Water soluble contrast enemas performed in the early postoperative period (mean: day 7 postoperatively, range: days 4‐14)
Number of subjects: 233
Study: 3922471

Group type: EXPERIMENTAL
Intervention: Cholestyramine enterocoated with cellulose acetate phthalate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31489588

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus best supportive care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 0
Study: 29272606

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking after a high-carbohydrate/low-fat meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 0
Study: 26724564

Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as Usual Group (CAUG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG) with high quality care environments
Number of subjects: 0
Study: 25211369

Group type: EXPERIMENTAL
Intervention: ticagrelor and acetylsalicylic acid (ASA) in combination with dabigatran (150 mg bid)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ticagrelor and acetylsalicylic acid (ASA) in combination with rivaroxaban (20 mg od)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ticagrelor and acetylsalicylic acid (ASA) in combination with phenprocoumon (INR 2.0‐3.0)
Number of subjects: 60
Study: 22920810

Group type: EXPERIMENTAL
Intervention: Aerobic games (exercise themed jogging)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Balance games (game themed)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aerobic games (hula hooping)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aerobic games (jogging)
Number of subjects: 100
Study: 19414203

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) with elevated HbA1c and waist circumference (WC) values
Number of subjects: 2603

Group type: COMPARATOR
Intervention: Normal fasting glucose (NFG) with normal HbA1c and waist circumference (WC) values
Number of subjects: 2603
Study: 17627484

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg nightly for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (identically appearing tablet nightly for 4 weeks)
Number of subjects: 10
Study: 16235184

Group type: EXPERIMENTAL
Intervention: Thrice-weekly trimethoprim-sulfamethoxazole (TS) for 12 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 240
Study: 11925400

Group type: EXPERIMENTAL
Intervention: Blastocyst culture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cleaving embryo transfer
Number of subjects: 0
Study: 9928752

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 51
Study: 8775070

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (SWL) for lower caliceal stones
Number of subjects: 219
Study: 2197095

Group type: EXPERIMENTAL
Intervention: Björk-Shiley (BS) prosthesis
Number of subjects: 178

Group type: COMPARATOR
Intervention: St Jude Medical (SJM) prosthesis
Number of subjects: 178
Study: 508687

Group type: EXPERIMENTAL
Intervention: Scatter xenon arc panretinal photocoagulation (15 eyes)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nontreatment group (19 eyes)
Number of subjects: 33
Study: 30306670

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation programme (VRP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: General physical exercise (Control Group)
Number of subjects: 47
Study: 28865890

Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: AF burden categories (0%, 0% to 99%, and 99% to 100%)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Baseline propeptide concentrations
Number of subjects: 102
Study: 26228394

Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Computer games control activities
Number of subjects: 78
Study: 23444161

Group type: EXPERIMENTAL
Intervention: Maxillary dentures with full palatal coverage (Group I, n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Maxillary dentures with partial palatal coverage (Group II, n = 9)
Number of subjects: 19
Study: 21502860

Group type: EXPERIMENTAL
Intervention: Seprafilm (hyaluronic acid-carboxymethylcellulose membrane)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no Seprafilm)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires (VAS-pain score, EQ-5D, SF-36)
Number of subjects: 71
Study: 19465422

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 329
Study: 16759740

Group type: EXPERIMENTAL
Intervention: Surgicept (70% ethanol, CHG, BZK, ethylhexylglycerin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Avagard (61% ethanol, 1% CHG)
Number of subjects: 0
Study: 15567095

Group type: EXPERIMENTAL
Intervention: V-1 Immunitor (V1) b.i.d.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 11149033

Group type: EXPERIMENTAL
Intervention: Dopamine alone (2.5 micrograms/kg/min for 2 postoperative days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dopamine + Mannitol (0.25 g/kg every 12 hours for 2 postoperative days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dopamine + Furosemide (1 mg/kg every 12 hours for 2 postoperative days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 9489083

Group type: EXPERIMENTAL
Intervention: Nisoldipine coat core (CC) 10 mg o.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg o.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisoldipine coat core (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study: 7691765

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate in non-thrombolytic group
Number of subjects: 109

Group type: COMPARATOR
Intervention: Ongoing fibrinolytic therapy
Number of subjects: 109
Study: 2864032

Group type: EXPERIMENTAL
Intervention: Family-based approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patient-oriented approach
Number of subjects: 36
Study: 31424431

Group type: EXPERIMENTAL
Intervention: Computer-based education (video and 3D animations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurse counseling (standard of care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-based education
Number of subjects: 0
Study: 29486348

Group type: EXPERIMENTAL
Intervention: Tuning Relationships with Music (intervention)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 26
Study: 27807527

Group type: EXPERIMENTAL
Intervention: Sling exercise group (SEG, n=34)
Number of subjects: 57

Group type: COMPARATOR
Intervention: General physical therapy group (PTG, n=23)
Number of subjects: 57
Study: 24508042

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine administered according to a 2-dose vaccination schedule (0, 12 months in study A and 0, 6 months in study B)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Statistical models for longitudinal data
Number of subjects: 281
Study: 22528571

Group type: EXPERIMENTAL
Intervention: Hand-sewn CEGA
Number of subjects: 174

Group type: COMPARATOR
Intervention: Stapled side-to-side CEGA
Number of subjects: 174
Study: 20583919

Group type: EXPERIMENTAL
Intervention: Microsurgical approach (TG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional macrosurgical technique (CG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study: 17908322

Group type: EXPERIMENTAL
Intervention: Specialized Emergency Nurses (SEN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: House Officers (HOs)
Number of subjects: 0
Study: 16061589

Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 898

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Additional analgesia with morphine
Number of subjects: 898
Study: 12370838

Group type: EXPERIMENTAL
Intervention: Glipizide GITS monotherapy (20 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (2.5 g/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (glipizide GITS + metformin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monotherapy (either glipizide GITS or metformin)
Number of subjects: 20
Study: 10077140

Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC albuterol
Number of subjects: 0
Study: 7672959

Group type: EXPERIMENTAL
Intervention: Frontal EMG biofeedback training (n = 8)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Trapezius EMG biofeedback training (n = 10)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation therapy (n = 8)
Number of subjects: 26
Study: 2149882

Group type: EXPERIMENTAL
Intervention: Remoxipride (high doses: 300-600 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 7023649

Group type: EXPERIMENTAL
Intervention: Weekly methotrexate
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Biweekly methotrexate with leucovorin rescue (ML)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Biweekly ML combined with cyclophosphamide and cytosine arabinoside (MLCC)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 259

Group type: COMPARATOR
Intervention: MLCC
Number of subjects: 259
Study: 31578895

Group type: EXPERIMENTAL
Intervention: Home-based salivary cortisol collection protocol
Number of subjects: 188
Study: 31067067

Group type: EXPERIMENTAL
Intervention: Middle Superior Alveolar (MSA) technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Infraorbital technique
Number of subjects: 30
Study: 28751519

Group type: EXPERIMENTAL
Intervention: Thrombus CT characteristics (location, distance from ICA terminus to thrombus, length, volume, absolute and relative density on NCCT, and perviousness)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Intra-arterial treatment
Number of subjects: 199
Study: 26540210

Group type: EXPERIMENTAL
Intervention: Combined home health education (HHE) plus trained general practitioner (GP) intervention
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 1341
Study: 23484176

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide bleaching gel
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20955400

Group type: EXPERIMENTAL
Intervention: Carbamazepine withdrawal
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Valproate withdrawal
Number of subjects: 124
Study: 19150180

Group type: EXPERIMENTAL
Intervention: Standardized laboratory speech stressor
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control task (no stressor)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Skin tests performed the day after the stressor
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Con A-stimulated leukocytes post-stressor
Number of subjects: 28
Study: 18321465

Group type: EXPERIMENTAL
Intervention: Ranibizumab + PDT
Number of subjects: 162

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 162
Study: 16033337

Group type: EXPERIMENTAL
Intervention: Apple juice (glucose 28 g in 250 ml) administered at 06:00‐06:30 am
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overnight fasting
Number of subjects: 100
Study: 12109009

Group type: EXPERIMENTAL
Intervention: In-class Web survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-class paper-and-pencil survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Take-home Web survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Take-home paper-and-pencil survey
Number of subjects: 0
Study: 11692351

Group type: EXPERIMENTAL
Intervention: Three-dimensional video glasses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Two-dimensional video glasses
Number of subjects: 24

Group type: COMPARATOR
Intervention: No video glasses (control)
Number of subjects: 24
Study: 7498222

Group type: EXPERIMENTAL
Intervention: 99mTc‐L,L‐EC
Number of subjects: 15

Group type: COMPARATOR
Intervention: 131I‐OIH
Number of subjects: 15
Study: 2100642

Group type: EXPERIMENTAL
Intervention: Pliva 60 diltiazem preparation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pliva 90 diltiazem preparation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Aldizem 90 diltiazem preparation
Number of subjects: 9
Study: 6800954

Group type: EXPERIMENTAL
Intervention: Group Y vaccine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Group W135 vaccine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Group Y-W135 combined vaccine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Monovalent vaccine (50 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Divalent vaccine (100 micrograms)
Number of subjects: 10
Study: 31740114

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 104

Group type: COMPARATOR
Intervention: HeartMate II or HeartWare Ventricular Assist Device (Control)
Number of subjects: 104
Study: 30157894

Group type: EXPERIMENTAL
Intervention: SWIS treatment (pre‐post‐follow‐up)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting List Control (WLC, pre‐post)
Number of subjects: 56
Study: 27161339

Group type: EXPERIMENTAL
Intervention: ECHO (Experienced Carer Helping Others) intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: ECHO intervention
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: ECHO and TAU
Number of subjects: 149
Study: 25490732

Group type: EXPERIMENTAL
Intervention: Brief parent-adolescent sexual risk communication intervention
Number of subjects: 2564
Study: 22205203

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 35 mg/m(2) in < 65 years group
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m(2), Gemcitabine 800 mg/m(2), Liposomal Doxorubicin 20 mg/m(2) in ≥ 65 years group
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combination therapy (Bortezomib, Gemcitabine, Liposomal Doxorubicin)
Number of subjects: 93
Study: 20631326

Group type: EXPERIMENTAL
Intervention: Zinc administration (10 mg/d for children 2-11 months and 20 mg/d for children ≥ 12 months) for 14 days
Number of subjects: 2599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Zinc administration
Number of subjects: 2599
Study: 18551467

Group type: EXPERIMENTAL
Intervention: Green tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black tea (0.3 g extract/250 ml) with 0.4 mg folic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Green tea (0.3 g extract/250 ml) with 5 mg folic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (reference drink) with 0.4 mg and 5 mg folic acid
Number of subjects: 0
Study: 17002050

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy regimen '2b' (isoniazid, rifampicin, pyrazinamide, ethambutol, fluoroquinolone (ofloxacin, ciprofloxacin, levofloxacin), and canamycin (amikacin))
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen '2a' (isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy regimen '2b'
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen '2a'
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conventional regimen '2b' in patients with MBT resistant to isoniazid
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional regimen '2a' in patients with MBT resistant to isoniazid
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conventional regimen '2b' in patients with MBT resistant to rifampicin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional regimen '2a' in patients with MBT resistant to rifampicin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Conventional regimen '2b' in multidrug resistance
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional regimen '2a' in multidrug resistance
Number of subjects: 75
Study: 12925338

Group type: EXPERIMENTAL
Intervention: Vestibular exercises (13 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo exercises (8 patients)
Number of subjects: 21
Study: 10375149

Group type: EXPERIMENTAL
Intervention: Consumer Assessment of Behavioral Health Services instrument
Number of subjects: 160
Study: 8931918

Group type: EXPERIMENTAL
Intervention: Schizophrenic children
Number of subjects: 57

Group type: COMPARATOR
Intervention: ADHD children
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 57
Study: 1706562

Group type: EXPERIMENTAL
Intervention: Clemastine 4 mg + Cimetidine 400 mg i.v. 15 min before implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bone cement implantation
Number of subjects: 40
Study: 6765509

Group type: EXPERIMENTAL
Intervention: 20 mg of triamcinolonehexacetonide (TH)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 6 mg of the combination betamethasone acetate and betamethasone disodiumphosphate (BM)
Number of subjects: 42
Study: 31647382

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) response
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 28685396

Group type: EXPERIMENTAL
Intervention: Bupropion HCl immediate release (IR) 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion HCl sustained release (SR) 100/150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion HCl extended release (ER) 150/300 mg
Number of subjects: 0